Evidence map›Paper›PMID 31445972›Full record

ArticleNeuroscience letters2019

Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors.

Elisabetta Perdona, Palmina Cavallini, Anna Sava, Cristiana Griffante, Daniel J Ricca, Karl B Thor, Nadia M J Rupniak, Mauro Corsi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Recent Developments in On-Demand Voiding Therapies.The Journal of pharmacology and experimental therapeutics · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Elisabetta PerdonaDrug Design and Discovery, Aptuit an Evotec Company, via A. Fleming 4, 37135 Verona, Italy.
Palmina CavalliniDrug Design and Discovery, Aptuit an Evotec Company, via A. Fleming 4, 37135 Verona, Italy.
Anna SavaDrug Design and Discovery, Aptuit an Evotec Company, via A. Fleming 4, 37135 Verona, Italy.
Cristiana GriffanteDrug Design and Discovery, Aptuit an Evotec Company, via A. Fleming 4, 37135 Verona, Italy.
Daniel J RiccaDignify Therapeutics LLC, Research Triangle Park, North Carolina, USA.
Karl B ThorDignify Therapeutics LLC, Research Triangle Park, North Carolina, USA.
Nadia M J RupniakDignify Therapeutics LLC, Research Triangle Park, North Carolina, USA. Electronic address: nrupniak@dignifytherapeutics.com.
Mauro CorsiDrug Design and Discovery, Aptuit an Evotec Company, via A. Fleming 4, 37135 Verona, Italy.
Aptuit (Italy) · ITTriangle · USDignify Therapeutics (United States) · US

Funding

An optimized NK2R agonist for 'on-demand' voidingR44AG055169 · NIA · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2017 to 2018
$1.8M
Identification of an optimized NK2R agonist for 'on-demand' voidingR43AG055169 · NIA · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2016 to 2016
$276k
NIA NIH HHS R43 AG055169NIA NIH HHS R44 AG055169
6 · The paper itself

Abstract

The affinity, potency, efficacy, and selectivity of the NK2 receptor agonist GR64349 ([Lys

Indexed as

AnimalsCHO CellsCricetulusHumansReceptors, Neurokinin-1Receptors, Neurokinin-2Recombinant ProteinsReceptors, Neurokinin-1Receptors, Neurokinin-2Recombinant ProteinsTACR1 protein, humanGR64349NK1 receptorTachykinin NK2 receptor

Identifiers

PMID31445972
PMCPMC6759388
OpenAlexW2969404391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.